4.6 Article

Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease

期刊

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 60, 期 2, 页码 243-251

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2021-0837

关键词

afamin; non-alcoholic liver disease; population-based studies; prediction; risk factors; vitamin E-binding protein

资金

  1. Academy of Finland [322098, 286284, 134309, 126925, 121584, 124282, 129378, 117787, 41071]
  2. Social Insurance Institution of Finland
  3. Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals [X51001]
  4. Juho Vainion Foundation
  5. Paavo Nurmi Foundation
  6. Finnish Foundation for Cardiovascular Research
  7. Finnish Cultural Foundation
  8. Sigrid Juselius Foundation
  9. Tampere Tuberculosis Foundation
  10. Emil Aaltonen Foundation
  11. Yrjo Jahnsson Foundation
  12. Diabetes Research Foundation of Finnish Diabetes Association
  13. European Union's Horizon 2020 Research and Innovation Program [848146, 755320]
  14. European Research Council [742927]
  15. Tampere University Hospital Supporting Foundation
  16. Finnish Society of Clinical Chemistry
  17. Austrian Research Fund [P19969-B11]
  18. Austrian Heart Fund
  19. Kamillo-Eisner Stiftung
  20. Medizinische Forschungsgesellschaft Salzburg
  21. Standortagentur Tirol
  22. Signe and Ane Gyllenberg Foundation

向作者/读者索取更多资源

This study found that afamin concentrations are significantly higher in patients with NAFLD and independently predict the development of NAFLD. In a population-based cohort followed for 10 years, afamin concentrations were positively associated with the development of NAFLD.
Objectives In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD. Methods Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up. Results Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23-1.54] per 10 mg/L increase, p<0.0001). Conclusions Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据